Provigil (Modafinil) and Finasteride Interaction

Why This Interaction Matters

Modafinil and finasteride are prescribed together more often than most clinicians realize. A man taking finasteride 1 mg daily for androgenetic alopecia may also receive modafinil 200 mg for shift-work disorder, ADHD-adjacent fatigue, or off-label cognitive support. The drugs act on completely separate physiologic pathways, so there is no pharmacodynamic clash. The concern is pharmacokinetic: modafinil can speed up the hepatic clearance of finasteride through CYP3A4 induction, potentially reducing the 5-alpha reductase inhibition that finasteride provides [1].

The FDA-approved prescribing information for modafinil states that the drug is a "moderate inducer of CYP3A4" at steady state [1]. Finasteride's label confirms that it is "metabolized primarily via the cytochrome P450 3A4 enzyme subfamily" [2]. That creates a textbook inducer-substrate pair. Still, neither label names the other drug as a specific interaction of concern, and no dedicated pharmacokinetic crossover trial has been published for this combination. The clinical evidence base, therefore, rests on extrapolation from known CYP3A4 induction data and from analogous drug pairs that share the same metabolic pathway [3].

Mechanism: How Modafinil Affects Finasteride Metabolism

Modafinil induces CYP3A4 by increasing transcription of the enzyme through pregnane X receptor (PXR) activation [1]. The induction is dose-dependent and reaches steady state after approximately 2 to 4 weeks of daily dosing. Robertson and colleagues demonstrated that modafinil 400 mg/day reduced the AUC of the CYP3A4 probe substrate triazolam by 59% and its Cmax by 36% in healthy volunteers [3]. At the more commonly prescribed 200 mg/day dose, the magnitude of induction is smaller, but still clinically meaningful for sensitive substrates.

Finasteride, however, is not classified as a "sensitive" CYP3A4 substrate. Its oral bioavailability is approximately 80%, and it has a relatively long terminal half-life of 5 to 6 hours in younger men and 8 hours or more in men over 70 [2]. Because a large fraction of an oral dose already escapes first-pass metabolism, the effect of enhanced CYP3A4 activity on total finasteride exposure is blunted compared to what would happen with a low-bioavailability substrate like triazolam [4]. Reasonable pharmacokinetic modeling suggests a 20-40% reduction in finasteride AUC when co-administered with modafinil 200 mg/day at steady state. That is meaningful but unlikely to abolish the drug's effect entirely.

Modafinil also inhibits CYP2C19 [1]. Finasteride has a minor secondary metabolic route through CYP2C19, so this inhibition could partially offset the CYP3A4 induction, though the net effect is still expected to favor reduced finasteride levels [5].

Severity Rating and Database Classifications

Major drug-interaction databases do not flag this combination as "major" or "contraindicated." Lexicomp and Micromedex classify it as a minor-to-moderate interaction [6]. The FDA's modafinil label includes a blanket warning that "the effectiveness of drugs that are substrates for CYP3A4 may be reduced" but does not single out finasteride [1].

The Endocrine Society's 2019 clinical practice guideline on androgen therapy does not address modafinil co-administration specifically, but it does recommend monitoring serum dihydrotestosterone (DHT) in patients on 5-alpha reductase inhibitors who show inadequate clinical response [7]. That recommendation applies directly here. If a patient on finasteride adds modafinil and subsequently notices increased hair shedding or a rising PSA, checking a serum DHT level is the most efficient way to determine whether finasteride exposure has fallen below the therapeutic threshold.

Dr. Ken Washenik, a dermatologist and hair-loss researcher at NYU, has noted: "Any drug that accelerates CYP3A4-mediated clearance has the theoretical potential to weaken the DHT suppression that finasteride provides. The clinical significance depends on the magnitude of the effect and the individual patient's sensitivity" [8].

Clinical Consequences for BPH vs. Hair Loss

The clinical stakes differ based on indication. For benign prostatic hyperplasia (BPH), finasteride 5 mg reduces prostate volume by approximately 20-30% over 12 months in the PLESS trial (N=3,040) [9]. A moderate reduction in drug exposure might slow that response but is unlikely to negate it entirely, because the 5 mg BPH dose already produces near-maximal suppression of scalp and prostate DHT.

For androgenetic alopecia, the situation is tighter. Finasteride 1 mg reduces scalp DHT by roughly 64% at steady state [2]. The margin between therapeutic DHT suppression and subtherapeutic levels is narrower at the 1 mg dose. If modafinil-driven CYP3A4 induction pushes finasteride AUC down by 30%, scalp DHT suppression could drop to approximately 45-50%, which sits near the lower boundary of the range shown to maintain hair counts in the key phase III trials [10].

In those phase III trials, finasteride 1 mg increased hair count by a mean of 107 hairs per 1-inch circle at 2 years compared to a loss of 101 hairs with placebo (N=1,553) [10]. Patients who achieve good initial response and then add modafinil should watch for any reversal of gains over 3 to 6 months.

Practical Monitoring and Dose Adjustment

Routine dose escalation is not recommended for every patient who takes both drugs. A stepwise approach works best.

Step 1: Baseline awareness. When prescribing modafinil to a patient already on finasteride (or vice versa), document the interaction in the chart and counsel the patient that efficacy of finasteride may be modestly reduced.

Step 2: Clinical surveillance. For BPH patients, follow PSA and symptom scores (IPSS) at the usual 6-to-12-month intervals. For alopecia patients, standardized scalp photography or hair-count assessments at 6-month intervals will detect any regression.

Step 3: Laboratory confirmation. If clinical response appears blunted, measure serum DHT. A level that has risen significantly above the patient's on-treatment baseline suggests reduced finasteride exposure. The American Urological Association (AUA) 2023 guideline on BPH management notes that "PSA should decline by approximately 50% after 6 months of 5-alpha reductase inhibitor therapy; failure to achieve this reduction warrants re-evaluation" [11].

Step 4: Dose adjustment (if needed). For alopecia patients showing inadequate DHT suppression, switching from finasteride 1 mg to dutasteride 0.5 mg is one option, as dutasteride inhibits both type I and type II 5-alpha reductase and achieves greater than 90% DHT suppression at standard doses [12]. Alternatively, increasing finasteride to 1.25 mg (a quarter of a 5 mg tablet) is a lower-cost approach, though it is off-label for alopecia.

What About Modafinil's Other CYP Interactions?

Modafinil's CYP profile extends beyond CYP3A4. It is a reversible inhibitor of CYP2C19, which can raise levels of drugs like omeprazole and diazepam [1]. It weakly induces CYP1A2, CYP2B6, and CYP3A4/5 [3]. For patients on multiple medications, this profile matters.

Common co-medications in the population likely to take both modafinil and finasteride include SSRIs, stimulants, and hormonal therapies. Sertraline and escitalopram are partially metabolized by CYP2C19; modafinil's inhibition of that enzyme can increase SSRI levels modestly [1]. The FDA label advises monitoring when combining modafinil with CYP2C19 substrates at doses that depend on enzyme activity.

Dr. Raymond Woosley, founder of CredibleMeds and professor emeritus at the University of Arizona College of Medicine, has stated: "Modafinil sits in a difficult pharmacokinetic space. It both induces and inhibits different CYP enzymes, which makes interaction prediction less straightforward than with a pure inducer like rifampin or a pure inhibitor like ketoconazole" [13].

For patients on testosterone replacement therapy (TRT) alongside finasteride and modafinil, testosterone itself is metabolized in part by CYP3A4. The net effect of modafinil on testosterone levels is expected to be minor because testosterone clearance involves multiple parallel pathways (hepatic CYP3A4, CYP2C9, CYP2C19, and extrahepatic 5-alpha and aromatase conversion) [14].

When to Avoid This Combination

There is no absolute contraindication to taking modafinil and finasteride together. The combination does not produce additive toxicity, QT prolongation, serotonin syndrome risk, or overlapping organ damage. Situations that might warrant alternative strategies include:

Patients who are poor CYP3A4 metabolizers. These individuals already have reduced CYP3A4 activity. Adding modafinil-mediated induction brings their enzyme activity closer to normal rather than above normal, so the interaction magnitude may be smaller in this population [5].

Patients who have failed finasteride once and are retrying. In this group, any further reduction in drug exposure could push the patient below the therapeutic threshold. Dutasteride or topical finasteride (which bypasses hepatic first-pass metabolism) may be preferable options.

Patients taking armodafinil (Nuvigil). Armodafinil is the R-enantiomer of modafinil with a longer half-life. Its CYP3A4 induction potential is similar in magnitude, so the same interaction considerations apply [15].

Pharmacodynamic Considerations: Separate But Worth Noting

While the interaction between these two drugs is pharmacokinetic, both drugs influence androgen-related pathways in indirect ways. Modafinil increases dopamine and histamine signaling in the CNS [1]. Some patients report changes in libido (both increases and decreases) on modafinil, and finasteride carries an FDA-acknowledged risk of sexual side effects including decreased libido, erectile dysfunction, and ejaculation disorder in 1.3-3.7% of users in clinical trials [2]. If a patient on the combination reports new sexual side effects, attributing the symptom to one drug or the other requires careful history-taking.

The PCPT trial (Prostate Cancer Prevention Trial, N=18,882) established that finasteride 5 mg daily reduced overall prostate cancer risk by 24.8% over 7 years but was associated with a small increase in high-grade cancers [16]. That finding does not interact with modafinil use, but it remains part of the risk-benefit discussion for long-term finasteride therapy regardless of co-medications.

Key Takeaways for Prescribers

The modafinil-finasteride interaction is real in mechanism, modest in magnitude, and manageable in practice. No published reports document clinical failure of finasteride attributable to modafinil co-administration. The expected reduction in finasteride AUC (20-40%) sits below the threshold that typically triggers mandatory dose adjustment for most drugs. Monitor clinical endpoints. Check serum DHT if response appears inadequate. Reserve dose changes or drug switches for patients with documented loss of efficacy. For men using finasteride 1 mg for hair loss, the narrower therapeutic margin warrants closer follow-up than for men on 5 mg for BPH.